Association of Programmed Death-Ligand 1 Expression with Aggressive Histological Types of Thyroid Carcinoma

References

• Rosai J, Albores SJ, Asioli S, Baloch ZW, Bogdanova T, Chen H. Tumours of the thyroid gland. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J, editors. WHO Classification of Tumours of Endocrine Organs. 4th ed. Geneva: WHO Press; 2017:81–91.
   Google Scholar
• Ceolin L, Duval M, Benini AF, Ferreira CV, Maia AL. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocr Relat Cancer. 2019;26:R499–R518. doi:10.1530/ERC-18-0574
   PubMed Web of Science ®Google Scholar
• Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:1–10. doi:10.1155/2013/965212
   Google Scholar
• Baloch ZW, LiVolsi VA. Special types of thyroid carcinoma. Histopathology. 2018;72:40–52. doi:10.1111/his.13348
   PubMed Web of Science ®Google Scholar
• Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol. 2010;22:395–404. doi:10.1016/j.clon.2010.05.004
   PubMed Web of Science ®Google Scholar
• Haddad RI, Nasr C, Bischoff L, et al. NCCN guidelines insights: thyroid carcinoma. J Natl Compr Canc Netw. 2018;16:1429–1440. doi:10.6004/jnccn.2018.0089
   PubMed Web of Science ®Google Scholar
• Paschke R, Lincke T, Muller SP, Kreissl MC, Dralle H, Fassnacht M. The treatment of well-differentiated thyroid carcinoma. Dtsch Arztebl Int. 2015;112:452–458. doi:10.3238/arztebl.2015.0452
   PubMed Web of Science ®Google Scholar
• Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. J Clin Pathol. 2018;71:189–194. doi:10.1136/jclinpath-2017-204853
   PubMed Web of Science ®Google Scholar
• Ulisse S, Tuccilli C, Sorrenti S, et al. PD-1 ligand expression in epithelial thyroid cancers: potential clinical implications. Int J Mol Sci. 2019;20:1–15. doi:10.3390/ijms20061405
   Web of Science ®Google Scholar
• Zhang GQ, Wei WJ, Song HJ, et al. Programmed cell death-ligand 1 overexpression in thyroid cancer. Endocr Pract. 2019;25:279–286. doi:10.4158/EP-2018-0342
   PubMed Web of Science ®Google Scholar
• Aghajani MJ, Yang T, McCafferty CE, Graham S, Wu X, Niles N. Predictive relevance of programmed cell death protein 1 and tumor-infiltrating lymphocyte expression in papillary thyroid cancer. Surgery. 2018;163:130–136. doi:10.1016/j.surg.2017.04.033
   PubMed Web of Science ®Google Scholar
• Ahn S, Kim TH, Kim SW, et al. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer. 2017;24:97–106. doi:10.1530/ERC-16-0421
   PubMed Web of Science ®Google Scholar
• Bai Y, Guo T, Huang X, et al. In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related. Virchows Arch. 2018;472:779–787. doi:10.1007/s00428-018-2357-6
   PubMed Web of Science ®Google Scholar
• Bai Y, Niu D, Huang X, et al. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. Diagn Pathol. 2017;12:72. doi:10.1186/s13000-017-0662-z
   PubMed Web of Science ®Google Scholar
• Bi Y, Ren X, Bai X, et al. PD-1/PD-L1 expressions in medullary thyroid carcinoma: clinicopathologic and prognostic analysis of Chinese population. Eur J Surg Oncol. 2019;45:353–358. doi:10.1016/j.ejso.2018.10.060
   PubMed Web of Science ®Google Scholar
• Capdevila J, Wirth LJ, Ernst T, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020;38:2620–2627. doi:10.1200/JCO.19.02727
   PubMed Web of Science ®Google Scholar
• Chintakuntlawar AV, Rumilla KM, Smith CY, et al. Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study. J Clin Endocrinol Metab. 2017;102:1943–1950. doi:10.1210/jc.2016-3756
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Veyhl J, Jessa F, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget. 2016;7:32318–32328. doi:10.18632/oncotarget.8698
   PubMed Web of Science ®Google Scholar
• Fadia M, Fookeerah P, Ali S, Shadbolt B, Greenaway T, Perampalam S. PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study. Pathology. 2020;52:318–322. doi:10.1016/j.pathol.2019.11.007
   PubMed Web of Science ®Google Scholar
• Girolami I, Pantanowitz L, Mete O, et al. Programmed Death-Ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma. Endocr Pathol. 2020;31:291–300. doi:10.1007/s12022-020-09630-5
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Z, Yan Z, Ma S. PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma. Adv Clin Exp Med. 2020;29:785–792. doi:10.17219/acem/121518
   PubMed Web of Science ®Google Scholar
• Shi RL, Qu N, Luo TX, et al. Programmed death-ligand 1 expression in papillary thyroid cancer and its correlation with clinicopathologic factors and recurrence. Thyroid. 2017;27:537–545. doi:10.1089/thy.2016.0228
   PubMed Web of Science ®Google Scholar
• Malone HE, Nicholl H, Coyne I. Fundamentals of estimating sample size. Nurse Res. 2016;23:21–25. doi:10.7748/nr.23.5.21.s5
   PubMedGoogle Scholar
• Ilie M, Khambata-Ford S, Copie-Bergman C, et al. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS One. 2017;12:1–13.
   Web of Science ®Google Scholar
• Zwaenepoel K, Jacobs J, De Meulenaere A, et al. CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy. Histopathology. 2017;71:357–365. doi:10.1111/his.13230
   PubMed Web of Science ®Google Scholar
• Kemal YY, Gün S, Çalışkan S, Kefeli M. 1926P PD-L1 expression in medullary thyroid carcinoma and its relevance with clinicopathological findings. Ann Oncol. 2020;31:S1090–S1. doi:10.1016/j.annonc.2020.08.1414
   PubMed Web of Science ®Google Scholar
• Bai Y, Kakudo K, Li Y, et al. Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type. Cancer Sci. 2008;99:1908–1915. doi:10.1111/j.1349-7006.2008.00908.x
   PubMed Web of Science ®Google Scholar
• Wan B, Deng P, Dai W, et al. Association between programmed cell death ligand 1 expression and thyroid cancer: a meta-analysis. Medicine. 2021;100(14):e25315. doi:10.1097/MD.0000000000025315
   PubMed Web of Science ®Google Scholar